scispace - formally typeset
E

Eric M. Bachelder

Researcher at University of North Carolina at Chapel Hill

Publications -  101
Citations -  3791

Eric M. Bachelder is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medicine & Adjuvant. The author has an hindex of 31, co-authored 81 publications receiving 2976 citations. Previous affiliations of Eric M. Bachelder include University of Nebraska–Lincoln & Ohio State University.

Papers
More filters
Journal ArticleDOI

Acetal-Derivatized Dextran: An Acid-Responsive Biodegradable Material for Therapeutic Applications

TL;DR: Owing to its ease of preparation, processability, pH-sensitivity, and biocompatibility, this type of modified dextran should find use in numerous drug delivery applications.
Journal ArticleDOI

Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy

TL;DR: In this article, a biocompatible material that can be formed into microparticles with degradation rates that are tunable over 2 orders of magnitude depending on the degree and type of acetal modification is presented.
Journal ArticleDOI

Fully Acid-Degradable Biocompatible Polyacetal Microparticles for Drug Delivery

TL;DR: The ease of preparation of the polymers coupled with the ability to tune their hydrophobicity and the high acid sensitivity of the microparticles identify this new class of materials as promising candidates for the delivery of bioactive materials.
Journal ArticleDOI

A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer

TL;DR: It is shown that liposomal nanoparticle-delivered cGAMP (cGAMP-NP) activates STING more effectively than soluble cGamp, and suggests that a minimal system comprised of cGamping-NP alone is sufficient to modulate the tumor microenvironment to effectively control PD-L1-insensitive TNBC.
Journal ArticleDOI

'Educated' dendritic cells act as messengers from memory to naive T helper cells.

TL;DR: Using chimeric mice generated by aggregation of two genotypically different embryos, it is found that the conversion of a naive T cell occurs only if it can interact with the same antigen-presenting cell, although not necessarily theSame antigen, as the effector T cell.